Drugs / T512
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03226470 | Mar 2017 → Feb 2022 | human papillomavirus-related squamous cell carcinoma | Huazhong University of Science and Technology | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T512 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03226470 ↗ |
| Action | Inhibit | “using designated TALENs (T27 and T512) targeted HPV16 E6 and E7 produced disruption of HPV16 E6 and E7 DNA, decreased the expression of E6 and E7 proteins” NCT03226470 ↗ |
| Route | Other | “T512 suppository” NCT03226470 ↗ |